FUNDAMENTALS · Fundamentals · NL Healthcare

argenx (ARGX) Fundamentals 2026 — P/E 48.5x, Revenue Analysis | SniperIQ

argenx (ARGX) is a NL-listed Healthcare company in Biotechnology with a market capitalization of $53.4B, trading at $858.22 on the NASDAQ. This SniperIQ fundamentals page covers argenx's valuation (P/E 48.5x, P/B 7.3x), profitability (net margin 33.4%), revenue ($4.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$53.4B
P/E (TTM)48.5x
Net Margin33.4%
Revenue (FY25)$4.2B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is argenx's market cap?

argenx (ARGX) has a market capitalization of approximately $53.4B, trading at $858.22 on the NASDAQ. Market cap moves with the live share price.

What is argenx's P/E ratio?

argenx's trailing twelve-month P/E ratio is 48.5x, with a price-to-book (P/B) of 7.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is argenx?

argenx runs a net profit margin of 33.4%, a gross margin of 89.0%, and an operating margin of 25.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does argenx generate?

argenx reported revenue of $4.2B for fiscal year 2025, with net income of

.3B and earnings per share (EPS) of 21.14. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does argenx pay a dividend?

argenx does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is argenx financially healthy?

argenx carries a debt-to-equity ratio of 0.01x and a current ratio of 5.23x, with a market beta of -0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is argenx a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For argenx (ARGX) the key facts are: market cap $53.4B, P/E 48.5x, revenue $4.2B, 52-week range 566.425-953.58. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track argenx's full fundamentals live

Get argenx's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Bora Pharmaceuticals (6472) fundamentals · Sinopharm Group (1099) fundamentals · Takeda Pharmaceutical (TAK) fundamentals · Cardinal Health (CAH) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons